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Dear Professor Stephen Mudge,  
 
I am writing to you in reference of Manuscript ID EM-ART-01-2014-000057 
(Title: Developing a modelling approach to predict pharmaceutical discharges from UK sewage 
treatment works using steroid estrogens as a case study) which was originally submitted to 
Environmental Science: Processes and Impacts in January 2014.  
 
We wish to thank yourself and the reviewers for providing such detailed feedback on our manuscript 
(reviewers comments received 23
rd
 April 2014). As suggested, we have fully addressed the concerns 
of the reviewers and are therefore resubmitting the revised manuscript for publication in 
Environmental Science: Processes & Impacts. The manuscript is now entitled: Parameterization of 
pharmaceutical emissions and removal rates for use in UK predicted exposure models: steroid 
estrogens as a case study. We have detailed our responses to the reviewers’ comments below. 
 
 
Yours sincerely 
 
Sean Comber 
 
Associate Professor (Senior Lecturer) in Environmental Sciences 
B525 Portland Square 
Plymouth University 
Drake Circus 
Plymouth 
Devon 
PL4 8AA 
T: +44(0)1752 585974 
E: sean.comber@plymouth.ac.uk 
 
 
Referee 1, Comment: The paper is not written that well so in some places it is hard to determine 
what exactly the authors have done. I suggest the authors re-work the text to make the messages 
clearer. 
 
It is difficult to address issues of poor writing without more explicit direction, especially when the 
second reviewer stated the paper was well written. Regardless, we have addressed a number of 
areas of text to ensure clarity of the message. 
 
Referee 1, Comment: I would suggest the title be changed. The paper seems to be about 
parameterization of emission data rather than developing a new modelling approach. A more 
accurate title would be something like ‘Paramaterization of emissions and removal rates for 
pharmaceuticals for use in exposure models’. 
 
We particularly value this comment and the guidance given – the title has been modified. 
 
Referee 1, Comment: Abstract, Line 2 – I don’t think you can say the method is accurate 
 
Addressed in manuscript. 
 
Referee 1, Comment: Abstract, Line 8 – ‘predictions’ not ‘predications’ 
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Addressed in manuscript. 
 
Referee 1, Comment: Page 1, Introduction, Line 6 – I think this sentence needs some supporting 
references. What evidence do the authors have that incorrect disposal is important? 
 
Addressed in manuscript. 
 
Referee 1, Comment: Page 2, Introduction, column 1, para 1, line 15 – would suggest ‘at’ rather than 
‘within’ 
 
Addressed in manuscript. 
 
Referee 1, Comment: Page 2, Introduction, column 1, para 2 – I think this paragraph (which provides 
the rationale for the paper) is very misleading and shows a limited understanding of the existing 
modelling approaches. The models described can be applied to any catchment if the hydrology and 
STP data are available. The models are also not specific to estrogens and have been applied to other 
compounds (numerous papers on this exist). It is also possible to parameterise the LowFlows model 
for specific treatment works using local data on prescriptions and STP-specific removal rates. This 
part of the introduction should be re-written. The authors are trying to suggest that their method is 
novel but really it isn’t that innovative. 
 
Addressed in manuscript. 
 
Referee 1, Comment: Page 2, Introduction, column 2, para 1 – The authors present this study as 
developing a new model. To me all they have done is use a good quality dataset to parameterise 
modelling concepts that have been around for some time. I think this section should be toned down. 
 
We feel that this section does not over-state what we have done, nor its relevance to the wider field, 
as it is simply a generalised description of the modelling approach and its potential application. We 
believe this section is of value in differentiating our approach, from other approaches seen in the 
literature i.e. ‘per-capita’ approach. However, we do appreciate the reviewers comments, and have 
made some small changes to tone down this section and make it more apparent that we are 
improving parameterisation, and building upon established modelling concepts (as opposed to 
creating a new model from scratch) – addressed in manuscript. 
 
Referee 1, Comment: Page 2  Model development and parameterisation – To me the authors have 
not developed a model but just described an approach to parameterise models. I suggest that this 
whole section is re-titled and reworded. 
 
See above and changes to manuscript 
 
Referee 1, Comment: Page 3, column 1, para 1 – I would like to see some background evidence for 
supporting some of the assumptions, particularly that tourism isn’t an issue. Couldn’t tourists 
‘import’ pharmaceuticals into the catchment and couldn’t this skew the predictions? 
 
The reviewer is absolutely correct that tourism could skew these predictions. However, as detailed, 
the data used is from outside of the main holiday season and thus influence of tourism is likely to be 
limited – this has been evidenced in the manuscript. Unfortunately it is not possible to evidence the 
other assumptions – namely as regards registration of residents, and within catchment excretion. 
The highly specific information needed to evidence such behaviour in a specific location is not 
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available – and it is therefore for this reason that the assumptions behind this modelling approach 
are clearly stated. 
 
Referee 1, Comment: Page 5, Figure 2 and accompanying text – The authors state that the results 
are comparable with measured data but I would like to see some justification for this. From the 
graph, it appears that the modelling under-predicts E1 and over-predicts EE2. The graph also 
indicates that the Williams and Johnson estimates for E1 are better than in the current study. The 
Williams and Johnson data are also not too far off so what is all the fuss about. 
 
The key point is that the relative proportions of E1, E2, EE2 in our predictions, better reflect the 
measured data than the previous model does. We have also emphasised the accuracy of our EE2 
predictions – something very important in relation to the proposed EQS.  Hence we have attributed 
this to use of local prescription data, rather than per capita i.e. therefore supporting our approach.  
 
Referee 1, Comment: Page 6, Table 2 – I am intrigued as to why the authors didn’t focus on a 
catchment where monitoring data were available. The paper would have been much stronger if it 
had been applied to a catchment that had some real data. The authors should consider doing this. 
 
This is a valid point, and we agree that section of a catchment where monitoring data were available 
would have benefited this study. However, there are a number of reasons why monitoring data were 
not available/used 
1) Little water quality data is available for estrogens in UK river waters owing to the low limits 
of detection needed and cost of analysis meaning that there is little data available anyway.   
2) The study location was selected due to its interesting demographics and rural location – as 
many models (and monitoring studies) are applied to high population density urban areas, 
we wished to tackle a generally unconsidered location. 
3) The CIP data provides a comprehensive, quality controlled dataset with which to calibrate 
the model.    
4) Additionally very few, if any, UK catchments have undergone in-depth routine monitoring of 
STW influents and effluents i.e. at every STW in a given catchment at an appropriate 
regularity to overcome issues around variability in removal performance; and therefore 
there is limited availability of data for comparison. Therefore (as discussed in the abstract) 
the general lack of measured sewage works data necessitates the development of an 
approach to allow comparison of local predictions with average national measurements  – 
hence our use of data from the recent UK wide STW survey. 
Words to this effect have been provided in the text.  
 
Referee 2, Comments: The authors suggest a new approach to estimating pharmaceutical 
concentrations entering and being discharged from STW 
 
The paper is well written and the results given by the authors are satisfactory. The authors  did a 
good job of motivating the work. 
 
The paper can be published in the Environmental Science Proceses & Impacts 
 
Referee 2, Comment – minor points: Can authors put an error bar for their prediction at figure 1 ? ( i 
mean 95% conf .int) 
 
We appreciate this comment; however inclusion of 95% confidence intervals for predicted influent 
loads is not possible without incorporating estimations of error within prescription data sets, 
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excretion rates, in sewer removal rates, etc. As these types of data are themselves of limited 
availability, there is no appropriate means to provide sensible estimates of error.  
 
Referee 2, Comment – minor points: Johnson and Williams published a model for the  prediction of 
estrogenic compounds in influent and effluent The authors have compared the result of their  model 
with the classic work of  Johnson & Williams in terms of influent load at Fig 2. However it would be 
much more interesting if they had a third column in table 2 with another model  ( like  J &W --> 
simplistic population group , or even their model with non update (old)  prescription database) in 
order to demonstrate the superiority of their model even only on the catchment. 
 
We understand why referee 2 has suggested this addition to table 2, to allow further comparison. 
However, the purpose of this figure is simply to illustrate improvements to the J&W model by taking 
account of local demographics / data. Therefore comparison of the outputs of this modelling 
approach with further model outputs (which also do not take account of localised data) is of limited 
value. 
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Increasing concern regarding the presence and effects of pharmaceuticals in water has led to 
changes in European legislation; with a number of pharmaceuticals named on a watch list as part of 
the Water Framework Directive. The potentially huge cost to the water industry to meet new 
standards requires accurate predictions of likely concentrations at a catchment scale, in order to 
target resources. This paper describes an environmental management tool to more accurately 
predict pharmaceutical loadings to rivers at a catchment scale, using a combination of recently 
available prescription data, metabolism and fate information and recent monitoring data to develop 
and calibrate a model to allow all stakeholders to identify sewage treatment works which pose the 
greatest risk to receiving waters. 
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consumed of synthetic estrogens, while use of highly localised census data improves 
predictions of naturally excreted estrogens by accounting for regional variations in population 
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catchment level, especially in light of newly proposed regulatory measures which may in 
future require removal of steroid estrogens by sewage treatment facilities. In addition, the 
general lack of measured sewage works data necessitated the development of a novel approach 
which allowed comparison of localised predictions to average national measurements of 
influent and effluent. Overall in the case study catchment, estrogen predictions obtained using 
the model described herein were within 95% confidence intervals of measured values drawn 
from across the UK, with large improvements to predictions of EE2 being made compared with 
previous predictive methods. 
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Introduction 
Human pharmaceuticals are now ubiquitous in the environment 
and are found as far afield as the Arctic [1]. The vast majority 
of human medicines enter the aquatic environment in sewage 
treatment works (STW) effluents, derived from excretion in 
urine or faeces or via the incorrect disposal of unused 
medications into household sewerage. Due to the general 
resistance of patients to taking medication [2], and their 
tendency to under-medicate [3], with typically 50% of 
prescribed pharmaceuticals not being administered [4], large 
quantities of unused pharmaceuticals can be generated. In the 
UK it is estimated that 85% of these unused medications are 
disposed of improperly (63% to landfill; 12% domestic waste 
water stream), and only 22% are returned to pharmacies as 
recommended [5].   Less significant loadings may be derived 
from combined sewer overflows, and contributions from 
landfill leachates are likely to be limited due to advancements 
in liners [6, 7]. Transport to the environment of these bioactive 
compounds, which can have deleterious effects upon biota [8, 
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9], is set to continue and is likely to be further exacerbated over 
the coming years due to factors such as an aging and 
increasingly obese population influencing drug usage [10-12]. 
Furthermore, the occurrence of drugs in drinking water has 
been an additional cause for concern [13, 14].  
In Europe these concerns have led to legislative reform, with 
selected pharmaceuticals (Diclofenac, 17-α-ethinylestradiol 
[EE2], 17-β-estradiol [E2]) now included in the Water 
Framework Directive [15, 16] as substances on a ‘watch list’ 
which requires Member States to undertake monitoring 
programmes and consider reduction in discharges to the 
environment where appropriate. Initial environmental quality 
standards (EQS) were proposed as 100, 0.035 and 0.4 ng L-1 as 
annual averages for Diclofenac, EE2 and E2 respectively. 
Treatment technologies are available to reduce pharmaceutical 
concentrations in wastewaters, however these raise financial 
and sustainability concerns [17]. A recent impact assessment 
estimated compliance costs for the UK water industry to meet 
proposed EQS for EE2 as over £20 billion [18]. It will therefore 
be necessary and pertinent to focus limited financial resources 
at ‘pollution hotspots’. One means by which to identify such 
hotspots is predictive modelling at a small geographical scale. 
This requires two key numbers to be derived; the concentration 
being discharged into receiving waters from STW and based on 
available dilutions [19, 20], predicted environmental 
concentrations which can be compared against relevant 
environmental quality standards. This paper sets out an 
approach for achieving the first objective by improving 
parameterisation of pharmaceutical usage, and subsequent 
quantities discharged from STWs. Other developmental work in 
the UK on modelling water quality [21] has the ability to take 
discharged loads and predict water quality based on predicted 
and measured flows.    
Catchment models have been developed to predict 
concentrations of chemicals such as pharmaceuticals in the 
aquatic environment (e.g. ‘Geography Referenced Regional 
Exposure Assessment Tool for European Rivers’ (GREAT-ER) 
and LowFlow2000-WQX [22, 23] for estrogens). They have 
been used to assess inputs from specific sources such as 
hospitals [24] or to predict pharmaceuticals such as estrogens 
for specific catchments using estimates of excretion rates based 
on assumptions regarding per capita use of estrogenic 
medications and demographics [25]. A model has been recently 
developed (SAGIS) that combines derived loads of 
contaminants discharged to surface waters from point and 
diffuse sources which is combined with a water quality model 
(SIMCAT) via a Geographic Information System (GIS) system 
to allow accurate predictions of a variety of chemicals in UK 
water bodies [21]. Generating accurate load data from the main 
sources such as STWs will generate load inputs for these types 
of models now being used by the Environment Agency and 
water industry for planning purposes. Such models rely entirely 
on the accuracy of the input data and so improvements in 
estimations of input loads strengthens the decision making 
process.  
To improve estimates of pharmaceutical loads it is essential to 
take account of the factors that influence endogenous 
production, exogenous usage, and therefore excretion of 
steroidal estrogens on a local scale. These include, but are not 
limited to, the population demographics, prescribing habits of 
local physicians, pregnancy rates and cultural views on 
contraception. Incorporation of these influencing factors into a 
model (as far as is possible) will therefore increase model 
validity at finer spatial resolution and improve reliability of the 
outputs.  
This research describes the development of a modelling 
approach that takes account of actual prescription data within 
specific catchments, alongside local demographic data, 
resulting in more refined predictions of these populations’ 
contribution to the environmental burden by improving 
parameterisation. In the following sections a case study, using 
estrogenic compounds and a selected catchment in England, is 
presented as an example of the model’s application. This case 
study uses census data [26] and prescription data [27, 28] 
encompassing all formulations of hormone replacement therapy 
including both E2 and conjugated estrogens (CE), and 
contraceptive pills containing EE2, to predict estrogen influent 
and effluent concentrations for a specific catchment, by 
building  upon established modelling concepts. A generic form 
of this approach, which may be applied to any river catchment, 
any STW, and any medication, for which prescription data is 
available, is provided in the electronic supporting information. 
The production of a modelling approach such as this, which is 
novel in its use of prescription data at highly localised scales 
(i.e. down to individual STW) and can be applied to any human 
pharmaceutical, is key in the development of strategies for the 
deployment of interventional approaches, including 
technological, to reduce pharmaceutical pollution; thus 
allowing finite resources to be targeted. 
Modelling Approach (Parameterisation) and 
Calibration  
River Catchment Identification  
A specific catchment was selected as a case study based on factors 
which included varying demographics and low river flows available 
for effluent to be diluted into (<10), thus indicating a potential risk 
of elevated levels of pharmaceuticals occurring in the aquatic 
environment downstream of the STWs [29]. Census data was 
obtained [26] to estimate population demographics and utilised for 
calculation of naturally excreted estrogens in the catchment. Whilst 
census statistical area boundaries do not generally conform to river 
catchments, Census Output Areas (COAs) are very small 
geographical units with a mean population around 300. A ‘best-fit’ 
selection of COAs to the catchment was made by overlaying the two 
sets of boundaries in GIS, resulting in a selection of 79 COAs. GIS 
analyses were conducted using ArcGIS 10 (ESRI, Redlands, CA) to 
derive population characteristics (Table 1). 
Table 1: Estimated Population Statistics for the Selected River 
Catchment, 2001 Census  
Total Population 22,199 
Female Population Age 13-49  4,737 
Female Population Age 50+  5,317 
Total Male Population 10,598 
Total Female Population  11,601 
Data source: UK Census 2001[26] 
Prescribed Synthetic Estrogens in the Selected Catchment  
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Isolation of Local Prescription Data STW discharge locations 
were plotted (GIS) and overlaid with the location of all General 
Practitioner (GP) surgeries in the region based upon postcodes; 
three GP surgeries were identified as serving the selected 
catchment. It was assumed that all residents were registered 
with GPs within this catchment and that all medication 
prescribed by these surgeries was excreted within the 
catchment. Any commuting to work was considered to have a 
neutral impact (i.e. as many people may travel to work in the 
catchment as travel out of the catchment to their place of work). 
Parts of the catchment are located near the coast, and so some 
seasonal influences could be expected. However, data obtained 
from England’s National Health Service (NHS) [27] detailed 
the number of monthly prescriptions written by each GP 
surgery between September of 2011 and January of 2012 and 
therefore out of the peak holiday season [30]. Although it 
would have been beneficial to work with data on a seasonal or 
yearly average basis, the NHS only began to release data in this 
format in September 2011, and this case study acts as an 
illustrative example. The NHS details this prescribing data in 
the form of British National Formulary (BNF) codes, which is a 
prescription guide routinely used by pharmacists and GPs in the 
UK. Details regarding the BNF codes are provided in the SI 
(S1).  
The prescribing data for BNF codes that included estradiol 
(E2), conjugated estrogens (CE) and ethinyl estradiol (EE2) 
were isolated from the dataset for analysis.  The average 
number of prescriptions per month for each relevant BNF code 
and each of the three GP surgeries within the selected river 
catchment was determined and summed; providing the total 
average number of monthly prescriptions written in the selected 
catchment for each relevant BNF code. Further prescription 
details can be found in the SI (Table S1). 
 
Conversion of number of prescriptions to prescribed mass 
Converting the number of prescriptions into a mass of 
prescribed estrogens in the selected catchment required the use 
of another data set. The NHS quarterly prescription cost 
analysis data for October-December 2011 [28], details the 
number of prescriptions for each individual formulation within 
all BNF codes, for the whole UK; datasets that are tied to GP 
locations only detail prescribing data down to BNF code i.e. not 
formulation level. This was used to ascertain typical prescribing 
practices in the UK, which were used with formulation-specific 
dosing information obtained from the BNF and online sources 
[31] to convert the localised prescription data for relevant BNF 
codes, to a mass of estrogens prescribed, while accounting for 
different formulations. The net result of these steps can be 
applied to any human pharmaceutical for which prescription 
data exists. An example of the application of this approach is 
provided in the SI (Tables S2 and S3). 
Synthetic and Natural Steroid Hormone Excretion  
The model developed by Johnson and Williams outlines a 
framework that identifies 5 major population groups which 
contribute to the environmental burden of estrogens [25]: 
pregnant females; menstrual females; menopausal females; 
menopausal females using hormone replacement therapy 
(HRT); and males. The method described herein and further 
detailed in SI (S1-S5) for calculating the use of synthetic 
estrogens in a target river catchment can be used to improve the 
accuracy in determining the contribution to environmental 
estrogen load from the population group “menopausal on HRT” 
and menstrual females using estrogen based contraceptives. The 
following sections summarize the variables considered when 
predicting excretion of synthetic and natural estrogens for all 
population groups. It should be noted that data used within 
models regarding excretion of pharmaceuticals and their 
metabolites can have a significant impact upon model outputs. 
For many pharmaceuticals there is a paucity of data regarding 
excretion rates, and many of the pharmacokinetic studies which 
generate these figures utilise radio-labelled compounds, and 
therefore do not account for metabolites. Additionally a number 
of other factors specific to the individual using the medicine, 
such as age and disease status, can also influence excretion 
rates. In the case of steroid estrogens the opposite scenario 
occurs with a wide range of highly variable and specific studies 
available from which to draw excretion data. An approach to 
take account of this variable data to establish an appropriate 
excretion rates for estrogenic compounds (as used herein) is 
described by A.C. Johnson and R.J. Williams [25]. 
 
Excretion of Synthetic E2 The source of synthetic E1 and E2 
is the excretion of metabolites from HRT. The method 
described above was used to calculate the ingestion of HRT 
medication in the selected catchment. The prescription data also 
allows for HRT usage to be broken down into estradiol (E2) 
and conjugated estrogen (CE) use, which provides a further 
increase in the accuracy of the model.  
The total daily ingestion of synthetic E2 in the selected river 
catchment was calculated, and using literature data it was 
assumed that 2.8% of ingested E2 [25] and 1.5% of ingested 
CE [32] are excreted in a potentially releasable form; including 
free E2 and the E2 glucuronide-conjugate (Figure 1). Summing 
the two provided the total E2 load discharged to sewer derived 
from estradiol and conjugated estrogen HRT. 
 
 
 
Figure 1: Summary schematic of synthetic and natural estrogen 
inputs, and removal during transport and treatment. (Note: Presented 
percentage removals during sewer transport and STW processing are 
refined removal rates - see S9, Table S5). 
 
Synthetic E1 Excretion Estradiol and conjugated estrogen 
hormone replacement therapies are also a source of E1 
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excretion and can therefore be calculated from women on HRT 
in a similar manner to synthetic E2 excretion. Using localised 
prescription data along with previously reported excretion rates, 
it is assumed that 1.4% of ingested E2 [25], and 7.2% of 
ingested CE [32] is excreted as potentially releasable E1 
(Figure 1). Adding these loads together provides the 
contribution of E1 excretion from estradiol HRT and CE 
therapy to the sewerage system. 
 
Excretion of Natural E1 and E2 
Pregnant Females Although pregnant women account for only 
a small proportion of the total populace, their per capita 
contribution to estrogen load can be upwards of 100 times 
greater than that of a menstruating, non-pregnant female [25]. 
Accurate demographic and birth rate data are therefore essential 
when predicting loads to sewer. There are many factors that 
influence the rate of pregnancy, which may include culture, 
socio-economic status, religion, views on contraception, and 
population demographics. By using localised census data the 
confounding effect of these variables, on regional changes in 
pregnancy rates, could be accounted for.  
Fertility rates are available annually for the UK [33] and are 
broken down into districts which include any given catchment 
of interest [34]. In 2010 the UK as a whole had a birth rate per 
capita of 1.3% and the selected district had a birth rate per 
capita of 0.88%. During the same period the Waltham Forest 
district outside of London had a rate of 2.1%. This disparity 
highlights the importance of using local data to account for 
societal and demographic differences in pregnancy rates. It 
should be noted that longitudinal studies demonstrate temporal 
variation in birth rates [35], as is exemplified by the UK baby 
boom of the 1960s, which can be due to a range of factors 
which can feature as a component of socio-economic status 
[36], such as social norms and financial incentives; thus it is 
necessary to update assumptions within models to take account 
of current trends. Since districts encompass areas larger than 
catchments, relevant district birth rates were broken down by 
age category and were used alongside corresponding census 
data for the identified catchment in order to improve accuracy. 
This derived a per capita rate of 1.0% live births for the 
selected catchment, which was used in further calculations. An 
additional factor (0.76) must then be applied to take account of 
multiple gestations and average gestational period of 40 weeks, 
i.e. on any given day there are approximately 23% less pregnant 
women than the yearly number of pregnancies [34]. It should 
be noted that this approach measures live births, which include 
all babies that are born with signs of life. Because of the 
incidence of multiple gestations, there are inherently more live 
births than maternities in a given population. In the UK, this 
equates to approximately a 1% difference. Having ascertained 
the number of pregnant women in the selected catchment, it 
was possible to determine this population group’s contribution 
to excreted potentially releasable E1 and E2 (free estrogens and 
glucuronated conjugates [25]; Figure 1). 
 
Menstrual Females Women of childbearing age that are not 
pregnant are the second most important contributors to 
naturally excreted estrogens. To accurately assign estrogen 
excretion from this population, the age range of females 
menstruating has to be defined. Previously the average for 
menarche was placed at 13.5 years [37]. A more recent study 
showed that the average age of menarche for girls in the US 
was 12.5 years, while also demonstrating an association 
between earlier age at menarche and factors such as increasing 
body mass index and black racial background [38]. On the 
other end of the spectrum, multiple reports support an age of 51 
as the natural age of menopause, with factors such as education, 
marital status, education, race and smoking status being 
implicated as independent predictors of either an increase or 
decrease in age at menopause [39, 40]. This is clear evidence 
that changing societal factors such as demographics and socio-
economic conditions are an important to consider with respect 
to the accuracy of model outputs. Before the onset of 
menopause, there is also a period of “perimenopause”, which is 
characterized by irregularity of menstrual periods that begins on 
average at the age of 47.5 [40]. Thus for the purposes of this 
model, women between and including the ages of 13 and 49 
and who are not pregnant were considered as part of the 
“menstrual female” population group. Applying this 
information to census information allowed excretion amount to 
be calculated (Figure 1). 
 
Menopausal Females Based upon the discussion of menstrual 
females, it follows that the population group menopausal 
females is defined as women of age 50 plus. However, when 
considering only the natural estrogen contribution from this 
population group, menopausal females using HRT must be 
excluded as their contribution has already been accounted for. 
Thus, this group is more accurately portrayed as “non-
medicated menopausal females”.  
In order to estimate the percentage of women in a population 
using HRT, recent trends in HRT use must be accounted for. In 
1994, it was estimated that 22% of postmenopausal females 
were using HRT pills; the statistic used within the Johnson and 
Williams (2004) model. Multiple studies have since shown that 
the use of HRT has decreased by an estimated 40-50%, due to 
concerns over associations with cancer and heart disease [41-
43]. Based on a conservative estimate of a 40% reduction, it 
can be estimated that only 13.2% of postmenopausal women 
currently use HRT. It should be noted that over 45% of the 
female population of the selected catchment was considered 
menopausal, compared with a UK average of 35% (reflecting 
the region’s attraction to retirees). It can therefore be expected 
that the synthetic estrogen load is increased owing to greater 
HRT use, whilst natural estrogen load would be lower because 
estrogen excretion among non-medicated menopausal females 
is considerably lower than that of menstrual females (Figure 1). 
 
Males Localised census data for the selected catchment allowed 
for more precise estimates of the male contribution to estrogen 
excretion (47.7% of the population) residing in the catchment. 
The excretion rate of potentially releasable estrogens for males 
has been reported elsewhere [25] (Figure 1); allowing 
calculation of E1 and E2 excreted by males within the 
catchment. 
 
EE2 Excretion Since the contraceptive pill is the only source 
of EE2 excretion, targeted prescription data is an exceptionally 
valuable tool for estimating EE2 in the environment. A load to 
sewer can be calculated on the basis of reported excretion of 
potentially releasable EE2 of 40% of the consumed mass [25] 
(Figure 1). 
 
Transformations and losses during sewer transport 
In-sewer transformations: previous studies Once within the 
sewerage system the concentration of pharmaceuticals is 
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amended by a complex set of physico-chemical and biological 
processes which result in de-conjugation of steroid sulphates 
and glucuronides, partitioning between solids and aqueous 
phases, and degradation of E2 to E1. Many of these effects are 
themselves heavily influenced by a variable range of factors 
including residence time, degree of oxygenation, suspended 
solids levels and bacterial assemblages present. The dynamics 
of sewerage systems have therefore influenced previously 
reported observations of steroid fate which show wide variance 
depending on ambient conditions. Previous studies have 
estimated and measured typical retention times for most sewer 
systems to be between 2 and 6 hours; this is considered too 
short and of insufficient biodegradation potential to 
significantly impact on E1 and EE2 concentrations [25, 44, 45]. 
However, it is widely accepted that E2 will degrade to some 
extent under these timescales and conditions to E1. Values vary 
between an estimated 50% degradation to E1 [25] to a between 
only 6 and 8% based on measured data [45]. These values are 
largely controlled by factors such as temperature, de-
conjugation rates and suspended solids levels. 
 
In-sewer transformations: this study The case study 
catchment and its attendant STWs were selected on the basis of 
available dilution within the watershed, identifying the 
catchment as a potential ‘hotspot’ for pharmaceuticals entering 
surface waters. This provided the opportunity to use it as a case 
study for the application of the model. Like most STW in the 
UK, there were no available routinely measured steroid data for 
crude sewage or effluents in the case study STW. Time and 
budget precluded sampling and determination of steroid 
estrogens in STW present within the case study catchment and 
therefore direct comparison between measured estrogen 
concentrations and concentrations modelled for the select 
catchment could not be performed. However, the application of 
English demographic data to the model (details provided in 
Supporting Information, page S6 and Table S3) enabled 
comparison with measured data from a recent detailed UK 
survey by generating predicted excretion data for England as a 
whole; thereby allowing optimisation of removal rates. 
Modification of model inputs to allow predictions for England 
are detailed in the supporting information (Page S6 and Table 
S3). 
The UK water industry has recently undertaken an extensive 
research programme to determine priority chemicals, including 
estrogens entering and being discharged from 25 STWs [46] 
(Figure 2). This dataset was generated under carefully 
controlled sampling and analysis conditions, with thorough 
quality assurance applied throughout. This has generated a 
valuable dataset with statistically rigorous summary statistics 
regarding concentration ranges and removal rates with which to 
compare the model outputs.  
 
Although the total E1 + E2 influent predicted for England by 
the model described herein (~16 µg capita-1 day-1) is less than 
the measured E1 + E2 influent (~22 µg capita-1 day-1), it was 
possible to utilise measured data to refine the value of the in-
sewer degradation rate of E2 to E1. When a 50% in-sewer 
degradation of E2 to E1 is assumed, the result is a predicted 
ratio of E1:E2 that differs considerably from measured values. 
Reduction of the degradation rate within the sewerage system 
will decrease E1 influent predictions, whilst increasing E2 
predictions, which allows for the ratio of the compounds in 
predicted data to calibrate with the measured data. In measured 
influent an E1:E2 ratio of 2.72 is observed, an identical E1:E2 
ratio is achieved in the model with a 28.8% transformation rate; 
thus providing a balance between observed and predicted E1 
and E2 concentrations entering STWs. Details of this ratio-
approach for the case study are detail in the SI (Pages S7-8; 
Table S4). 
 
 
 
Figure 2: Comparison of predictions of influent steroid loads 
between this study, previous predictions and measured data drawn 
from across the UK. Error bars represent ± 1 standard deviation. 
Predictions for this work (catchment and England) were performed 
with sewer removal rate of 28.75% (E2 to E1 transformation). 
 
The data in Figure 2 above and Table S4 of the SI shows the 
outcome of the calibration exercise and clearly illustrate that 
predicted influent quantities of the three compounds were 
proportionally comparable with those measured across a 
number of UK STWs. Due to the ratio calibration approach 
used this is hardly surprising for E1 and E2, however EE2 
influent predictions were not adjusted (i.e. assumed no in-sewer 
losses) and despite this the relative proportions of all 3 
compounds when taken together align well with measured data 
versus previous model outputs. Although there are variations 
between predicted influent concentrations for the catchment 
and England they are not significant and can be explained via 
differences in demographics (detailed below). For other 
pharmaceuticals much greater variation in local versus national 
estimates may be expected as drug use may be more polarised. 
For example use of beta blockers and statins in aging 
populations in retirement biased locations, elevated 
antidepressant use in socially deprived areas and antibiotics use 
on a seasonal basis or in the event of an outbreak of an 
infectious disease. It is therefore important to consider the 
benefit of locally derived estimates across the range of 
pharmaceutical use, not just estrogens.     
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Predicted E1 influent loads for England (10.4 µg capita-1 day-1) 
were within two standard deviations of the measured mean 
(mean of 10.4 with ± 2σ = 8.3 to 24 µg capita-1 day-1). The 
observed variation may, in part, reflect the demographics of the 
catchment. Pregnant women dominate the amount of E1 and E2 
excreted and so any small variations in catchment 
demographics could impact significantly upon predicted 
influent loads to the STWs. The equivalent E1 predictions for 
England (12.0 µg capita-1 day-1) are also less than measured 
values, and could indicate that an alternative source of E1 has 
not been accounted for in the model which could include 
prepubertal children [47, 48] and individuals not registered on 
the census (including holidaymakers). Although animals such 
as cattle, sheep, pigs, poultry and domestic animals naturally 
excrete E1 and E2 [49, 50]; their contribution to the sewerage 
system would not be expected to be significant, with the 
exception of possible veterinarian discharges.  
A similar situation exists for E2 where estimates from this 
research generate STW influent loads of 3.9 µg capita-1 day-1 
for the selected catchment, and 4.4 for England as a whole; 
similar to the value of 3.3 predicted previously [25], but less 
than that measured in the UK survey of 5.9 µg capita-1 day-1. 
The data in the model shows the significance of regional 
variations in demographics associated with proportion of 
pregnant females and age variations.   
Predicted influent loads of EE2 for England were 0.5 µg capita-
1 day-1 compared with a measured average value of 0.31 µg 
capita-1 day-1. However, this is closer to the measured data than 
achieved in a previous model (0.89 µg capita-1 day-1), and is 
also within +1 standard deviation of observed values. 
Variations may be owing to the assumption that all prescribed 
medication was consumed, which is not necessarily the case 
[51] which would lead to over estimation of actual loads. In 
consideration of this influencing factor, it would also be logical 
to argue that E1 and E2 influent concentrations should also be 
modified to reflect HRT compliance rates. However, drug 
adherence in HRT users is high (98.9% compliance [52]) and 
so would have a limited impact on excretion and influent 
predictions. Other physico-chemical characteristics of EE2 such 
as its higher log Kow [50] may also mean a degree of 
partitioning to biofilms present in the sewerage system thereby 
reducing levels at the STW. The different predictions of EE2 
effluent concentrations seen in a previous study compared with 
measured and modelled data presented here (Figure 2) may be 
explained by assumptions used for estimating populations of 
women using the contraceptive pill. From 2006-2010, the 
Center for Disease Control and Prevention reported that use of 
oral contraceptives was 17% of women aged 15-44 in the US 
[53]. As of 2011, 39.8% of the total UK female population is 
between 15 and 44 [34]. Assuming that use of the pill in 
England does not differ from the US, only 6.8% of all females 
in the UK (i.e. regardless of age) are using the contraceptive 
pill. Previous estimates also cited the same CDC source, but 
used a figure of 17% of all women using the pill [25]. The 
difference between 17% and 6.8% is approximately 60%, 
remarkably similar to the 56% difference in EE2 influent 
predicted by both methods. 
Transformations and losses during sewage treatment 
From a risk assessment point of view the wide ranging removal 
levels observed during different types of STW processes generate a 
large degree of uncertainty, which needs to be accounted for when 
assessing likely effluent concentrations. This uncertainty can be 
quantified by substituting different removal rates and comparing 
predicted effluent concentrations with those measured across UK 
STWs. STW removal rates could be modified to ensure that 
predicted and measured effluent values match, however this would 
not take account of the differential influent concentrations seen, nor 
variability in the relative proportions of the three compounds in 
predicted influent. Therefore a ratio-approach similar to that used 
during sewer transformation calculations was used to refine STW 
removal rates for use within the model, and considered removal rates 
across all treatment types and under specific processes. This exercise 
is detailed in the supporting information (Page S9, Table S5) and 
resulted in refined removal rate ranges of 58-84, 89-96 and 53-71% 
for E1, E2 and EE2 respectively. 
The variability in the measured effluent levels (Table 2) is 
significantly higher than that of the influent loads, reflecting the 
variations in removal rates within the STW (S8, Figure S1) leading 
to a wider range of observed effluent concentrations (Table 2). This 
demonstrates that there is still a significant amount of research 
required to identify (and eventually model) specific mechanisms 
within STW which control the removal processes. Nevertheless, 
accepting the inevitable uncertainty, predicted ranges of effluent 
concentrations (for England and the selected catchment) and 
measured effluent concentrations (expressed as 95 percentile 
confidence intervals around the means) overlap for all steroids. 
Predictions for the catchment are different from measured data due 
to population differences; highlighting the importance of accounting 
for local demographics in such risk exercises.  
 
Table 2: Summary of predicted data for select catchment and 
England, using refined removal rates 
Selected Catchment England 
 
E1 E2 EE2 E1 E2 EE2 
Load to sewer 
per capita  
(µg d-1) 
8.82 5.44 0.42 10.22 6.19 0.50 
Catchment 
population 
22199 
2219
9 
221
99 
49138
832 
4913
8832 
4913
8832 
Load to Sewer 
(mg d-1) 
196 121 9.4 
50205
1 
3039
25 
2458
7 
% loss in sewer 
+29%  
(from 
E2) 
-29%  
(to 
E1) 
0 
+29%  
(from 
E2) 
-29%  
(to 
E1) 
0 
Influent load 
(mg d-1) 
230.5 86.0 9.4 
58942
9 
2165
46 
2458
7 
Influent flow to 
STW  
(m3 d-1) 
5550 5550 
555
0 
12284
708 
1228
4708 
1228
4708 
Predicted 
influent (ng L-1) 
41.5 15.5 1.7 48.0 17.6 2.0 
Range of 
removal during 
treatment (%) 
58 – 
84 
89 -
96 
53 - 
71 
58 – 
84 
89 -
96 
53 - 
71 
Predicted range* 
for effluent 
(ng L-1) 
6.6 - 
17.5 
0.6 - 
1.8 
0.5 - 
0.8 
7.7 - 
20.2 
0.7 - 
2.0 
0.6 - 
0.9 
Measured range* 
for effluent  
 (ng L-1) 
   
10.9 – 
24.7 
1.3– 
3.9 
0.33– 
0.78 
* 95% confidence interval around the mean 
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Implications 
With predicted concentrations generated, it was possible to 
assess potential compliance with water quality standards. 
Currently in the EU pharmaceuticals are not included in water 
quality assessments. However, predicted no effect 
concentrations have been derived in the UK [54], and include a 
provisional value of between 3 and 5 ng L-1 for E1. At an EU 
level provisional EQS have been derived for E2 and EE2 (0.4 
and 0.035 ng L-1 respectively) but have not been currently 
implemented in lieu of additional data being sought [15]. 
Comparing ranges for predicted effluent quality, for the 
catchment and England, with these values demonstrates that for 
E1 a dilution of 2.2 to 5.8, and 2.6 to 6.7 respectively, would be 
required to ensure compliance with the downstream EQS 
assuming there is no E1 present upstream of the effluent 
discharge. For E2 a similar situation arises with dilution of 
between 1.4 and 4.4 for the catchment, and 1.6 and 5.0 for 
England required. For EE2, however, as the EQS is so low, 
then dilutions of 14 to 23, and 17 to 27, for the catchment and 
England respectively would be necessary. Given that the 
selected case study catchment was chosen owing to its low 
available dilution (<10) the risk assessment suggests that 
downstream concentrations of EE2 may exceed the derived 
EQS. Recent reported data [29] suggests that between 1 and 5% 
of STW in the UK (depending on STW removal rate) would not 
have sufficient dilution to guarantee compliance with the EE2 
EQS after mixing of effluent with receiving waters, leading to 
an estimate of £26 billion [16] in additional treatment to reduce 
effluent concentrations. 
In 2004 Johnson and Williams published a model for the 
prediction of estrogenic compounds in influent and effluent. 
The simplistic population group approach used for predicting 
excretion of these compounds requires a minimum of data and 
hence has been a popular approach used in a number of 
different models. The modelling approach described herein 
updates many of the parameters used to correspond with the 
socio-economic and cultural changes seen since its publication. 
Significantly more accurate estimates of EE2 achieved using 
the modelling approach described herein, demonstrate the 
importance of using available up-to-date information and 
databases (in this case prescriptions in particular), in order to 
update and refine models which can be used for screening 
purposes to assess possible compliance with new legislation. 
Additionally the provision of new prescription data sets within 
England, have allowed predictions for the excretion of 
synthetically derived compounds to be more accurately 
incorporated (as evidenced in particular by the improved EE2 
predictions generated herein), for specific geographical 
locations. Furthermore, the approach for calculating usage of 
synthetic compounds can be used in isolation, to predict 
excretion rates for pharmaceuticals which do not have a natural 
source. The availability of highly localised census data has also 
allowed more refined predictions of natural excretion of 
estrogen compounds, and highlights the importance of 
performing these types of risk assessment at small geographical 
scales e.g. catchment level. Improvements in sample processing 
and trace analysis of drugs in complex matrices have resulted in 
recent provision of measured data on pharmaceutical 
concentrations for both influent and effluent. The use of such 
measured data has allowed improvements to removal rate 
assumptions (during sewer transport and within STWs) used 
within this modelling approach, by utilising novel ratio-
approaches, thereby further increasing opportunities for 
calibration and thus predictive accuracy.  
This new approach to estimating pharmaceutical concentrations 
entering and being discharged from STW moves modelling 
capability forward in the UK. The case study data derived for 
the steroid estrogens provides excellent comparison with 
measured influent and effluent concentrations with significant 
improvements in accuracy of EE2 loads and concentrations. 
This is particularly important as future river water standards are 
likely to be set at very low (potentially sub ng L-1) values, 
which emphasises the importance of being able to accurately 
predict concentrations when considering programmes of 
measures to improve water quality.  
The development of a modelling approach, such as that 
presented herein, which can predict influent and effluent 
concentrations at scales as small as individual STW will be 
important in targeting limited remediation resources when 
legislation regarding priority substances comes into force. This 
is particularly important as environmental improvements under 
the Water Framework Directive are being focussed on a 
catchment scale with stakeholders such as sewage treatment 
companies needing to identify works at risk of contributing to 
EQS exceedances. The fact that local demographics could lead 
to significantly varying influent/effluent concentrations which 
may also be seasonal in character emphasises the necessity of 
being able to model this variability, particularly in areas where 
tourism is the main industry. Water companies hold 
information on holiday populations within sewer catchments 
which could be used to adjust the excreted loads based on the 
assumption for example that the incoming population were of 
similar demographics and being prescribed similar medication.   
The applicability of this modelling approach to any 
pharmaceutical is reliant upon data or estimates of excretion 
rates, removal rates in sewer and STW. With improving 
analytical methodologies being developed and an increasing 
concern regarding the discharge and fate of pharmaceuticals in 
the environment, it is anticipated that an increasing dataset will 
be generated in the coming years, driven by legislation such as 
the Water Framework Directive in the EU, which will provide 
input data for modelling approaches such as the one presented 
here.    
The NHS prescription database details millions of prescriptions 
per month which makes large scale (e.g. whole of England) 
assessment of ‘hotspots’ very challenging. However, this could 
be considered in the future when sufficient data is available 
(this database has only been available since September 2011). 
This may be even more significant where local demographical 
variations in pharmaceutical use may vary more significantly 
than for use of steroid estrogens. Examples could include use of 
anti-depressants in socially deprived areas, beta blockers and 
statins in retirement biased populations or the seasonal use of 
antibiotics. 
 
Acknowledgements 
The European Centre for Environment and Human Health (part 
of the University of Exeter Medical School) is part financed by 
the European Regional Development Fund Programme 2007 to 
2013 and European Social Fund Convergence Programme for 
Cornwall and the Isles of Scilly. This work was facilitated in 
part by a grant from the Global Health Scholar Fund at the 
University of Miami Miller School of Medicine. We thank N. 
Goodyear from The Nickwick Papers for assistance with figure 
production. We also thank UK Water Industry Research 
(UKWIR) for supplying UK STW data for steroids. We are 
grateful to the NHS for provision of data. Please note that NHS 
data on prescriptions is subject to copyright: Copyright © 2011, 
Page 13 of 27 Environmental Science: Processes & Impacts
ARTICLE Journal Name 
8 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 2012 
Re-used with the permission of The Health and Social Care 
Information Centre.  All rights reserved. 
 
Notes and references 
a European Centre for Environment and Human Health, University of 
Exeter Medical School, Truro, Cornwall, UK. 
b School of Geography, Earth and Environmental Sciences, University of 
Plymouth, Plymouth, Devon, UK. 
c University of Miami, University of Miami Miller School of Medicine, 
Department of Public Health Sciences, Miami, Florida, United States. 
 
Electronic Supplementary Information (SI) available: The Supporting 
Information, including 5 Tables and 1 Figure, provides a description of 
the method used, by detailing the datasets used, and using example data 
from the case study to illustrate the steps involved in predicting steroid 
usage, excretion and removal during sewer transport and within STWs to 
derive predicted influent and effluent concentrations. Additionally, a 
generalised formula for use in other case studies is provided, along with 
an explanation of how modifications were applied to derive estimations 
for England, along with data and discussion regarding removal rates and 
associated references. See DOI: 10.1039/b000000x/ 
 
 
 
 
 
1. R. Kallenborn, R. Fick, R. Lindberg, M. Moe, K.M. Nielsen, M. 
Tysklind, and T. Vasskog, Pharmaceutical residues in 
northern European environments: consequences and 
perspectives, in Pharmaceuticals in the Environment: Sources, 
Fate, Effects and Risks, K. Kummerer, Editor. 2008, Springer: 
Berlin / Heidelberg / New York 61. 
2. P. Pound, N. Britten, M. Morgan, L. Yardley, C. Pope, G. Daker-
White, and R. Campbell, Social science & medicine, 2005. 
61(1), 133. 
3. K. Pollock and J. Grime, Social science & medicine, 2000. 51(12), 
1827. 
4. R.B. Haynes, E. Ackloo, N. Sahota, H.P. McDonald, and X. Yao, 
Cochrane Db. Syst. Rev., 2008. 2(2). 
5. J.P. Bound and N. Voulvoulis, Envi. Health. Perpec., 2005. 113, 
1705. 
6. Y. Kawagoshi, Y. Fujita, I. Kishi, and I. Fukunaga, J. Environ. 
Monit., 2003. 5(2), 269. 
7. P.J. Phillips, A.T. Chalmers, J.L. Gray, D.W. Kolpin, W.T. Foreman, 
and G.R. Wall, Environ. Sci. Technol., 2012. 46(10), 5336. 
8. M.A. Taggart, K.R. Senacha, R.E. Green, Y.V. Jhala, B. Raghavan, 
A.R. Rahmani, R. Cuthbert, D.J. Pain, and A.A. Meharg, 
Environment International, 2007. 33(6), 759. 
9. N. Gilbert, Nature, 2011. 476, 265. 
10. R. Muenz, in SP Discussion Paper: Number 07032007, Social 
Protection, The World Bank: Washington. 1. 
11. The Royal Commission on Environmental Pollution, 2011, The 
Royal Commission on Environmental Pollution: United 
Kingdom. 
12. M. Depledge, Nature, 2011. 478, 36. 
13. R. Hooper, in New. Sci: Environ.2009: Online: 
http://www.newscientist.com/article/dn16397-top-11-
compounds-in-us-drinking-water.html. 
14. World Health Organisation, in Reference number: 
WHO/HSE/WSH/11.05, W.H. Organisation, Editor 2011. 
15. European Union, 2012: Brussels, 31.1.2012, COM(2011) 876 final, 
2011/0429 (COD). 
16. European Union, 2012: Brussels, 31.1.2012, SEC(2011) 1547 final. 
17. R. Owen and S. Jobling, Nature, 2012. 485(7399), 441. 
18. House of Commons Science and Technology Committee, 2013. 
19. C. Ort, J. Hollender, M. Schaerer, and H. Siegrist, Environmental 
Science & Technology, 2009. 43(9), 3214. 
20. A.C. Johnson, Environmental Science & Technology, 2010. 44(20), 
7865. 
21. S.D. Comber, R. Smith, P. Daldorph, M.J. Gardner, C. Constantino, 
and B. Ellor, Environmental Science & Technology, 2013. 
47(17), 9824. 
22. R. Williams, A. Johnson, V. Keller, A. Young, M. Holmes, and C. 
Wells, 2008, Environment Agency: Bristol. 
23. R.J. Williams, V.D.J. Keller, A.C. Johnson, A.R. Young, M.G.R. 
Holmes, C. Wells, M. Gross-Sorokin, and R. Benstead, 
Environ. Toxicol. Chem., 2009. 28(1), 220. 
24. K. Le Corre, C. Ort, D. Kateley, B. Allen, B.I. Escher, and J. Keller, 
Environ. Int., 2012. 45, 99. 
25. A.C. Johnson and R.J. Williams, Environ. Sci. Technol., 2004. 
38(13), 3649. 
26. UK Office for National Statistics, UK Data Service Census Support: 
http://casweb.mimas.ac.uk. 
27. National Health Service, 2011: The Health and Social Care 
Information Centre. 
28. National Health Service, 2011: The Information Centre for Health 
and Social Care. 
29. S. Comber, M. Gardner, R. Smith, P. Daldorph, and K. Murrell, 
2012, UK Water Industry Research (UKWIR): Queen Anne’s 
Gate, London, UK. 
30. The South West Research Company, 2012, Visit Cornwall: 
http://www.visitcornwall.com/industry/research#.U7qlQZRdV
fR. 
31. MIMS. 2012  [cited 2012 2 August 2012]; Available from: 
www.mims.co.uk/Drugs/. 
32. R.N. Johnson, R.P. Masserano, B.T. Kho, and W.P. Adams, Journal 
of Pharmaceutical Sciences, 1978. 67(9), 1218. 
33. UK Office for National Statistics, 2011. 
34. UK Office for National Statistics, 2011. 
35. S.V. Glinianaia, J. Rankin, T. Pless-Mulloli, M.S. Pearce, M. 
Charlton, and L. Parker, BMC pregnancy and childbirth, 2008. 
8(1), 39. 
36. H. Engelhardt, T. Kögel, and A. Prskawetz, Population Studies, 
2004. 58(1), 109. 
37. W.A. Marshall and J.M. Tanner, Arch. Dis. Child., 1969. 44(235), 
291. 
38. S.E. Anderson, G.E. Dallal, and A. Must, Pediatrics, 2003. 111(4), 
844. 
39. E.B. Gold, J. Bromberger, S. Crawford, S. Samuels, G.A. Greendale, 
S.D. Harlow, and J. Skurnick, Am. J. Epidemiol., 2001. 153(9), 
865. 
Page 14 of 27Environmental Science: Processes & Impacts
Journal Name ARTICLE 
This journal is © The Royal Society of Chemistry 2012 J. Name., 2012, 00, 1-3 | 9  
40. S.M. McKinlay, D.J. Brambilla, and J.G. Posner, Maturitas, 1992. 
14(2), 103. 
41. A.L. Hersh, M.L. Stefanick, and R.S. Stafford, J. Am. Med. Assoc., 
2004. 291(1), 47. 
42. B. Lawton, S. Rose, D. McLeod, and A. Dowell, Brit. Med. J., 2003. 
327(7419), 845. 
43. S.A. Tsai, M.L. Stefanick, and R.S. Stafford, Menopause (New York, 
NY), 2011. 18(4), 385. 
44. M.E. Jarvie, 2007, Michigan Technological University. 
45. M.E. Jarvie and D.W. Hand, Water Environment Research, 2009. 
81(2), 131. 
46. M. Gardner, V. Jones, S. Comber, M. Scrimshaw, T. Coello-Garcia, 
E. Cartmell, J. Lester, and B. Ellor, Sci. Total Environ., 2013. 
456-457, 359. 
47. F. Courant, L. Aksglaede, J.-P. Antignac, F. Monteau, K. Sorensen, 
A.-M. Andersson, N.E. Skakkebaek, A. Juul, and B.L. Bizec, 
J. Clin. Endocrin. Metab., 2010. 95(1), 82. 
48. D. Gupta, A. Attanasio, and S. Raff, J. Clin. Endocrin. Metab., 1975. 
40(4), 636. 
49. P. Matthiessen, D. Arnold, A. Johnson, T. Pepper, T. Pottinger, and 
K. Pulman, Sci. Tot. Environ., 2006. 367(2), 616. 
50. G.-G. Ying, R.S. Kookana, and Y.-J. Ru, Environment International, 
2002. 28(6), 545. 
51. M.Y. Hou, S. Hurwitz, E. Kavanagh, J. Fortin, and A.B. Goldberg, 
Obstet. Gynecol., 2010. 116(3), 633. 
52. B.-S.S.M. Torgerson Dj, J. Am. Med. Assoc., 2001. 285(22), 2891. 
53. J. Jones, W. Mosher, and K. Daniels, Natl. Vital. Stat. Rep., 2012. 60. 
54. Environment Agency, 2004  
 
 
Page 15 of 27 Environmental Science: Processes & Impacts
SUPPORTING INFORMATION 
Manuscript Title: Parameterization of pharmaceutical emissions and removal rates for use 
in UK predicted exposure models: steroid estrogens as a case study 
Authors: J. D. Heffley
1,3
, S. D. W. Comber
2
, B. W. Wheeler
1
, C. H. Redshaw
1
 
1
European Centre for Environment and Human Health, University of Exeter Medical School, 
Truro, Cornwall, UK. 
2
School of Geography, Earth and Environmental Sciences, University of Plymouth, 
Plymouth, Devon, UK. 
3
University of Miami, University of Miami Miller School of Medicine, Department of Public 
Health Sciences, Miami, Florida, United States. 
Contents: 
• Predicting synthetic estrogen usage: a case study      S1-S5 
o Understanding the dataset: British National Formulary (BNF) codes   S1 
 Table S1: Estrogen prescription data for the selected river catchment   S1 
o Conversion of number of prescriptions to prescribed mass    S2-S3 
 Table S2: Formulation level data for BNF code 070301F0    S3  
o Formulae for a generalised method to predict prescription usage    S4-S5 
• Modifying case study model inputs to generate predictions for England   S6 
o Table S3 Comparison between demographics and modelled estrogen excretion rates for the select 
catchment and England as a whole       S6 
• Predicting in-sewer transformations: a case study      S7 
o Table S4: Comparative findings for the case study catchment: influent loads  S7 
o Description of ratio-approach used to ascertain in-sewer transformation rate  S8 
• Predicting losses during sewage treatment: a case study     S9-S11 
o Figure S1: Reported STW removal rates for estrogens previously measured or estimated S9 
o Table S5: Optimised STW removal rates (based upon a ratio approach) for calculation of predicted 
effluents          S10 
• References for SI         S11-S12 
Page 16 of 27Environmental Science: Processes & Impacts
S1 
 
Predicting Synthetic Estrogen Usage: A Case Study 
Understanding the dataset: British National Formulary (BNF) codes 
The BNF is split into chapters (i.e. endocrine system), and further divided into multiple sections (i.e. 
sex hormones, female sex hormones, oestrogens and hormone replacement therapy), which are then 
further classified as codes for specific pharmaceuticals and combinations of pharmaceuticals (i.e. 
Combined Ethinylestradiol 30mcg”). These codes are often comprised of a number of different 
formulations, which vary by brand, dose and/or route of administration; no specific coding or 
labelling is given for individual formulations. For example, in the UK there are 16 different 
formulations within the BNF code for “Combined Ethinylestradiol 30mcg” (BNF code 070301F0). 
The mass of active ingredient in each formulation may differ over a range of brands, routes of 
administration, or combinations with other drugs (see S1 for case study example). 
 
Table S1: Estrogen Prescription Data for the Selected River Catchment  
Mean number of prescriptions calculated across 01.09.11 to 31.01.12. Source: National Health Service, Prescribing by 
GP Practice, The Information Centre for Health and Social Care, 2011 [1].   
 Average prescriptions per month (Rt) 
Pharmaceutical name & BNF Code GP Surgery 
1 
GP Surgery 
2 
GP Surgery 
3 
Total for selected 
catchment 
Estradiol (systemic) 0604011G0 48.6 22.8 25.4 96.8 
Estradiol Valerate 0604011K0 2.6 7.2 3.4 13.2 
Estradiol with Progestogen 0604011L0 28.2 15 21 64.2 
Estradiol (topical) 0702010Ga0 35.2 14 28.2 77.4 
Estradiol Val & Estradiol Val + Dienogest 
0703010R0 
0 0.2 0 0.2 
Oestrogens Conjugated 0604011P0 4.6 6.8 6.4 17.8 
Oestrogens Conjugated with Progestogen 
0604011Q0 
0.8 5 5.2 11 
Combined Ethinylestradiol 20mcg 703000 1.6 2.2 11.4 15.2 
Ethinylestradiol 0604011D0 2.2 0 1.4 3.6 
Combined Ethinylestradiol 30mcg 070301F0 59.8 39.8 70.8 170.4 
Combined Ethinylestradiol 35mcg 070301G0 19.6 7.6 7.4 34.6 
Phased Formulations Of Ethinylestradiol 
070301P0 
0.8 1.8 5 7.6 
Co-Cyprindiol (Cyprote Acet/Ethinlestr) 
1306020C0 
2 1 3.2 6.2 
Etonogestrel/Ethinylestradiol 070301A0 0 0 0.2 0.2 
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Conversion of number of prescriptions to prescribed mass 
In the UK there are 16 different formulations within the BNF code for “Combined Ethinylestradiol 
30mcg” (BNF code 070301F0; table S1). The mass of active ingredient in each formulation may 
differ over a range of brands, routes of administration, or combinations with other drugs, but in this 
particular case all formulations contained 30 micrograms of EE2. NHS data [2] detailed for the UK 
as a whole the number of prescriptions written for each individual formulation () and the quantity 
of drug dispensed (). The units for  depend upon how each individual formulation is dispensed, 
and can be a “pill”, “pack”, “millilitre”, “gram”, “capsule”, etc.  To illustrate this point, data for 
“Loestrin 30_Tab” (which is a formulation within BNF code 070301F0) is discussed (see table S2). 
There were 24,528 prescriptions written and 2,380,457 pills of Loestrin 30_Tab dispensed in the UK 
between October and December of 2011. Therefore each prescription of Loestrin 30_Tab contained 
on average 97 pills, which equates to 2.91 mg of active ingredient (Table S2). The average mass of 
active ingredient per prescription for each formulation of EE2 (,), across the whole of the UK was 
calculated in this manner (Eq S1; Table S2); however this did not account for regional (or catchment 
level) prescribed mass. 
As localised prescription data is not detailed down to the individual formulation level (only BNF 
codes), it was necessary to ascertain the relative proportion of each formulation prescribed within 
each BNF code to obtain typical UK wide prescribing practices, which could then be applied to 
localised catchment level data. For example, 3% of the 934,016 “Combined Ethinylestradiol 30mcg” 
(BNF code 070301F0) prescriptions written in the UK were of the “Loestrin 30_Tab” formulation 
(Eq S2; Table S2). Assuming that the prescription habits of GPs are uniform throughout the UK, 3% 
of the 170.4 monthly prescriptions for “Combined Ethinylestradiol 30mcg” in the selected river 
catchment were the “Loestrin 30_Tab” formulation (Eq S3). This output was then used in 
conjunction with average mass per prescription (Eq S1) of a specific drug formula to calculate the 
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total mass of Loestrin 30_Tab prescribed in this catchment per month and per day (Eq S4). A 
simplified summary formula covering all stages of calculation is presented in Eq S5 summary. This 
process was repeated for all formulations contained within each BNF code of interest and were then 
summed to give the total mass prescribed for each chemical of interest (E2, EE2, CE) (Eq S5).  
 
 
Table S2: Formulation level data for BNF code 070301F0  
Formulation 
Name 
EE2 
dosage 
(mg) 
() 
Items 
(1000’s) 
(	
) 
Quantity  
(1000’s) 
() 
Mean mass 
per 
prescription 
(mg) 
(	) 
Proportion 
prescribed 
() 
Number of 
prescriptions 
/ month for 
catchment 
(
) 
Mass 
prescribed 
per day  for 
catchment 
(mg) 
() 
Elevin_Tab 
150mcg/30mcg 0.03 2.33 222.48 2.87 0.00 0.42 0.04 
Femodene 
ED_Tab 0.023 1.20 135.42 2.54 0.00 0.22 0.02 
Femodene_Tab 0.03 36.5 3651.70 3.00 0.04 6.66 0.66 
Gedarel_Tab 
30/150mcg 0.03 18.7 1800.22 2.88 0.02 3.42 0.32 
Katya 30/75_Tab 0.03 0.20 17.87 2.65 0.00 0.04 0.00 
Levest 
150/30_Tab 0.03 12.10 1194.52 2.96 0.01 2.21 0.21 
Levest 
150/30_Tab 
(Actavis) 0.03 1.18 114.67 2.92 0.00 0.22 0.02 
Loestrin 30_Tab 0.03 24.53 2380.46 2.91 0.03 4.47 0.43 
Marvelon_Tab 0.03 47.99 4718.38 2.95 0.05 8.76 0.85 
Microgynon 30 
ED_Tab 0.0225 26.94 3171.78 2.65 0.03 4.91 0.43 
Microgynon 
30_Tab 0.03 492.78 48562.78 2.96 0.53 89.90 8.74 
Millinette_Tab 
30/75mcg 0.03 2.41 231.32 2.89 0.00 0.44 0.04 
Minulet_Tab 0.03 0.00 0.25 3.78 0.00 0.00 0.00 
Ovranette_Tab 
150mcg/30mcg 0.03 46.79 4488.25 2.88 0.05 8.54 0.81 
Rigevidon_Tab 0.03 39.97 3953.00 2.97 0.04 7.29 0.71 
Yasmin_Tab 0.03 180.39 17653.28 2.94 0.19 32.91 3.18 
Totals  934.02 (	) 170.40 () 
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Formulae for a generalised method to predict prescription usage 
A general method for determining daily use of prescription medications in a targeted catchment is 
presented below. 
Eq S1. The average mass per prescription for a specific drug formulation, ,, is given by  
, =

  
where  is the mass of a single dose of a given formulation,  is the quantity of doses 
dispensed of this formation in the UK within a given time frame  (e.g. number of pills dispensed 
from October-December 2011), and  is the number of prescriptions written of a given formulation 
UK wide (within the same time frame as ).  
Eq S2. The relative proportion prescribed of each formulation on a UK wide basis within a given 
BNF code, , is given by  
 =	

 	 
Where  is the sum of all  within a given BNF code. 
 
Eq S3. The number of prescriptions written of a given formulation in a localised catchment per 
month,	, can then be estimated by   
 =  
where  is the average number of prescriptions written per month in the catchment for a 
given BNF code (from Table S1).  
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Eq S4. The mass prescribed for each formulation in a given BNF code per month in the targeted 
catchment, , can now be calculated by  
 = , 
which can be converted to the daily mass prescribed of each formulation in a given BNF 
code, , which is given by  
 =	
12
365  
Eq S5. The series of equations above can be simplified to the following formula: 
 =
12
365  
Eq S6. To ascertain the total mass of a drug prescribed in a given catchment this series of 
calculations was repeated for each formulation within each BNF code of a given chemical, e.g. all 47 
formulations of EE2 which are contained within all 7 BNF codes that include EE2. This method of 
determining the mass of pharmaceuticals used is contingent on the assumption that all prescribed 
medications are actually ingested by the patient. Typically, only 50% of prescriptions are taken [3], 
but data suggests that patient adherence to contraceptive and HRT regimens is much higher [4, 5]. 
Therefore, assuming all prescribed medications are consumed, the sum of all  across all BNF 
codes containing a given chemical is the total daily consumption for the given chemical in the target 
catchment, , and can be given by  
 =,

 
 
where ! is equal to the number of formulations of a given chemical and the subscript " 
denotes the "th formulation of a given chemical.  
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Modifying case study model inputs to generate predictions for England  
As there was no measured crude sewage steroid data for the select catchment, the modelling 
approach developed was modified to apply English population values to the results of the case study 
excretion predictions, in order to allow comparison with measured sewerage influent data for 
England as a whole. For the values based on prescription data (HRT users and EE2 excretion), this 
modification is predicated on the assumption that prescribing practices for physicians in the case 
study catchment mimic those of physicians in England as a whole. Outputs from this modification 
and a description of the process are presented in Table 3. 
Total excretion (natural + synthetic) in mg day
-1
 
CASE STUDY 
CATCHMENT 
ENGLAND 
Population Group 
% of 
catchment 
Population 
% of 
England’s 
Population 
E1 E2 EE2 E1 E2 EE2 
A. Pregnant 0.78 0.99 95.15 67.99 0 267020 190798 0 
B. Menstrual Females   
(not pregnant) 
20.60 24.37 53.40 14.60 9.37 140121 38324 24587 
C. HRT users 3.16 2.38 11.34 14.45 0 18881 24059 0 
D. Menopausal Females (non-
medicated) 
20.80 15.64 8.31 4.62 0 13835 7686 0 
E. Males 47.70 48.68 27.55 19.08 0 62194 43057 0 
Average for total population of area (µg / day / capita) 8.82 5.44 0.42 10.22 6.19 0.50 
Table S3: Comparison between demographics and modelled estrogen excretion rates for the 
select catchment and England as a whole 
Population percentages are calculated from 2001 census data [6] by completing the following calculations, followed by 
conversion to a percentage of total population: A = population x birth rate x multiplier accounting for pregnancy 
duration; B = female population aged 13-49 minus the number of pregnant females; C = female population aged 50+ x 
HRT usage rate (13.2%); D = female population aged 50+ - number of HRT users; E = obtained from census data. 
Average per capita excretion data is presented in reference to total population (i.e. adults and children). Total natural 
excretion was calculated based upon figures detailed in the manuscript (Figure 1) and census data. Total synthetic 
excretion for England was based upon average catchment level per capita excretion of synthetic compounds (mass 
excreted in catchment ÷ number of individuals in corresponding catchment population group) and English population 
group specific demographics. Total natural and synthetic excretion were summed and divided by the total population size 
to find average for total population of area. 
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Predicting in-sewer transformations: a case study 
The UK water industry has recently undertaken a £30 million research programme to determine 
priority chemicals entering STW, impacts of primary, secondary and tertiary treatment and effluent 
concentrations. A total of 25 STW were sampled over the course of a year and influent 
concentrations and removal rates calculated for chemicals including the steroid estrogens [7]. Table 
S4 provide a summary of the influent data reported in an earlier predictive study, the UK Chemical 
Investigation Programme and this modelling approach (using a range of E1 to E2 transformation 
rates). For the purpose of an accurate comparison, concentrations have been calculated as µg capita
-1
 
day
-1
.    
 E1 E2 EE2 
Predicted influent (µg capita
-1
 day
-1
) – this work, select catchment; 
50% E2 to E1 conversion 
11.5 2.72 0.42 
Predicted influent (µg capita
-1
 day
-1
) – this work, select catchment; 
28.75% E2 to E1 conversion 
10.4 3.88 0.42 
Predicted influent (µg capita
-1
 day
-1
) – this work, select catchment;  
6% E2 to E1 conversion 
9.1 5.11 0.42 
Predicted influent (µg capita
-1
 day
-1
) – this work, England as a 
whole; 50% E2 to E1 conversion 
13.3 3.09 0.5 
Predicted influent (µg capita
-1
 day
-1
) – this work, England as a 
whole; 28.75% E2 to E1 conversion 
12.0 4.41 0.5 
Predicted influent (µg capita-1 day-1) – this work, England as a 
whole; 6% E2 to E1 conversion 
10.6 5.81 0.5 
Predicted influent (µg capita
-1
 day
-1
) – [8] 13.8 3.30 0.89 
Mean measure influent (µg capita
-1
 day
-1
) - [7] 16.1 5.90 0.31 
Median influent (µg capita
-1
 day
-1
) - [7] 16.7 5.90 0.23 
Standard Deviation (µg capita
-1
 day
-1
) - [7] 3.9 1.4 0.21 
Range (µg capita
-1
 day
-1
) - [7] 7.6-25.9 3.1-9.6 0.12-1.12 
 
Table S4: Comparative findings for the case study catchment: influent loads  
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Description of Ratio-Approach used to ascertain In-Sewer Transformation rates 
Based upon Johnson and Williams assumption of 50% degradation of E2 to E1, the modelling 
approach developed herein and modified with English demographics data, predicts E1 and E2 
influent loads of 13.3 and 3.09 µg capita
-1
 day
-1
 respectively, which is in line with Johnson and 
Williams predictions (E1 = 13.8, E2 = 3.30 µg capita
-1 
day
-1
), but is lower than measured means (E1 
= 16.1, E2 = 5.9 µg capita
-1 
day
-1
). Reduction of the degradation rate within the sewerage system will 
decrease E1 influent predictions, but increase E2 predictions. However, as predicted E1 + E2 equates 
to ~16 µg capita
-1 
day
-1
 in total, modification of the sewer removal rate will not result in achieving 
the higher values seen in measured data for both compounds simultaneously. Therefore sewer 
removal rates were optimised to achieve the same ratio of E1:E2 observed in the measured data. An 
identical E1:E2 ratio of 2.72 is achieved with a 28.75% removal rate; resulting in E1 and E2 
predictions of 12.0 and 4.41 µg capita
-1
 day
-1
 respectively, with an ‘optimised value’ of 75% of the 
observed influent values, for the England prediction. Lowering the removal rate further, to the 6% 
indicated in the findings of M.E. Jarvie and D.W. Hand [9], changes the E1:E2 ratio to 1.82, 
resulting in substantially higher proportions of E2 relative to E1 than is found in observed data, with 
98% and 66% of observed values for E2 and E1 being predicted, respectively. Based on this 
empirical data it may therefore be concluded that using a value of 28.75% loss of E2, with 
subsequent conversion to E1, within the sewer system, is the most accurate assumption for the 
purpose of this risk assessment for achieving realistic predictions of E1 and E2 simultaneously. 
Application of this 28.75% removal rate to the catchment scale model, results in E1 and E2 
predictions of 10.4 and 3.88 µg capita
-1
 day
-1
 respectively. 
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Predicting losses during sewage treatment: a case study 
The data (Figure S1) show that measured E1 and E2 removal rates are similar to those used in 
previous risk assessments and are within the 95% confidence intervals. For EE2, however, a very 
different result is observed, with previous estimates using a removal rate of 85%. The recent UK data 
however, generated widely varying removal rates, of between 0 and 92% with a mean of only 27% 
and median of 52% [7], greater removal rates were achieved with increased biological treatment, 
including nitrifying processes for ammonia removal (Figure S1). One explanation for this is 
analytical errors and measurements below the limit of detection which lead to ranges much more 
extreme than those calculated for E1 and E2, which are present at an order of magnitude or higher. 
 
Figure S1: Reported STW removal rates for estrogens previously measured or estimated  
Error bars represent 95% confidence intervals for overall mean removal and variations in median removal rates between 
activated sludge processes (ASP) and biological filter works (trickling filter: TF) 
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E1 E2 EE2 
Predicted influent (ng L
-1
) 48.0 17.6 2.0 
Measured Effluent (ng L
-1
)  
[& % observed removal] 
Mean all STW 17.8   [63] 2.6   [85] 0.56   [27] 
Median all STW 10.9   [80] 1.3   [93] 0.36   [28] 
Range for all STW  
(95% conf) 
10.9 – 24.7 1.3 – 3.9 0.33 – 0.78 
Median TF only 27.1   [44] 2.7   [81] 0.58   [53] 
Median ASP only 10.3   [83] 0.88  [94] 0.36   [64] 
Required predicted: measured ratio 0.75 0.75 1.61 
Predicted Effluent  
(ng L
-1
; using optimised % 
removal) 
Mean all STW 13.3 1.9 0.9 
Median all STW 8.1 1.0 0.6 
Median TF only 20.2 2.0 0.9 
Median ASP only 7.7 0.7 0.6 
Optimised % removal 
Mean all STW 72.3 89.0 54.9 
Median all STW 83.1 94.5 71.0 
Median TF only 57.9 88.6 53.3 
Median ASP only 84.0 96.3 71.0 
Range 58 – 84 89 – 96 53 - 71 
 
Table S5: Optimised STW removal rates (based upon a ratio approach) for calculation of 
predicted effluents 
Predicted data presented above are for the case study presented herein, for England’s population demographics. Predicted 
influent concentrations are calculated on a basis of 28.8% sewer transformation of E2 to E1. Required 
predicted:measured ratio is calculated from influent data (Table S4).  
Optimised removal rates for E1 and E2 correlate well with observed rates (i.e. mean & median across 
all STW; median TF and median ASP; Table S5). Of more interest are the optimised removal rates 
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generated for EE2. For specific STW types EE2 optimised removal rates (ASP 71%; TF 53%) and 
measured removal rates (ASP 64%; TF 53%) are alike. However, when the specific STW processes 
are not considered, and average or median values across different types of STW are used, optimised 
removal rates are found to be double those observed. These findings therefore suggest that use of 
predictive models would achieve more accurate effluent predictions if the specific treatment 
processes at a given works is taken into consideration. However, in the absence of process data for 
the works within the case study catchment, the optimised removal rates (calculated upon England’s 
demographic data and presented above) were applied, resulting in effluent concentrations as 
summarised (Table S5). 
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